THERAPEUTIC BENEFIT OF POTASSIUM CHANNEL ACTIVATORS IN TRIPLE-NEGATIVE BREAST CANCER

$444,416FY2020Defense Health AgencyDOD

University Of Illinois

Investigators

THERAPEUTIC BENEFIT OF POTASSIUM CHANNEL ACTIVATORS IN TRIPLE-NEGATIVE BREAST CANCER · GrantIndex